Ceritinib is a new generation selective tyrosine kinase inhibitor of ALK that provided longer progression-free survival than chemotherapy in NSCLC patients harboring an anaplastic lymphoma receptor tyrosine kinase gene rearrangement when used as the first line therapy in a randomized global phase 3 trial [1]. Here, ALK is linked to non-small cell lung carcinoma.